<DOC>
	<DOCNO>NCT00003445</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel treat patient advanced cancer cervix .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Advanced Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity docetaxel neoadjuvant chemotherapy patient locally advance squamous cell carcinoma cervix . II . Assess tumor response , toxic effect , survival rate regimen patient . OUTLINE : Patients receive docetaxel IV 1 hour day 1 . Treatment repeat every 3 week 3 course . Patients follow every 3 month posttreatment . PROJECTED ACCRUAL : A total 16-35 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIB , IIIA , IIIB , IVA squamous cell carcinoma cervix Bidimensionally measurable disease No bilateral hydronefrosis PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 10 g/dL Leukocytes least 4,000/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin le 1.25 time upper limit normal ( ULN ) AST le 1.25 time ULN Renal : BUN le 30 mg/dL AND Creatinine less 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No prior concurrent malignancy , properly treat basal cell skin cancer PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>